Document is current
Any future updates will be listed below
-
Authors
Reck, Martin https://orcid.org/0000-0002-5348-4462
Frost, Nikolaj https://orcid.org/0000-0001-7452-7129
Peters, Solange
Fox, Bernard A.
Ferrara, Roberto
Savai, Rajkumar https://orcid.org/0000-0003-1538-2091
Barlesi, Fabrice https://orcid.org/0000-0001-5793-3539
- License Information
-
More Information
Article History
Accepted: 10 July 2025
First Online: 14 August 2025
Competing interests
: M.R. has acted as a speaker and/or consultant for AbbVie, Amgen, AstraZeneca, Beigene, Boehringer-Ingelheim, BMS, Daiichi-Sankyo, Gilead, GSK, Lilly, Merck-Serono, MSD, Novartis, Pfizer, PharmaMar, Pierre-Fabre, Regeneron and Roche. N.F. has acted as a speaker and/or consultant for AbbVie, Amgen, AstraZeneca, BeiGene, Berlinchemie, Boehringer-Ingelheim, BMS, Lilly, Merck, MSD, Novartis, Pfizer, Roche, Sanofi and Takeda; and has received research funding from Roche. S.P. has acted as a consultant for AbbVie, Amgen, Arcus, AstraZeneca, Bayer, Beigene, BioNTech, BerGenBio, Bicycle Therapeutics, Biocartis, BioInvent, Blueprint Medicines, Boehringer-Ingelhim, BMS, Clovis, Daiichi Sankyo, Debiopharm, Lilly, F-Star, Foundation Medicine, Genmab, Genzyme, Gilead, GSK, Hutchmed, Illumina, Incyte, Ipsen, iTeos, Janssen, Qlucore, Merck, Novocure, PharmaMar, Promontory Therapeutics, Pfizer, Regeneron, Roche/Genentech, Sanofi, Seattle Genetics, Takeda and Zymeworks; has acted as a speaker for AstraZeneca, Boehringer-Ingelheim, BMS, Lilly, Foundation Medicine, GSK, Illumina, Ipsen, MSD, Mirati, Novartis, Pfizer, Roche, Sanofi, Seattle Genetics and Takeda; and has received research funding for trials sponsored by Amgen, Arcus, AstraZeneca, Beigene, BMS, Lilly, GSK, iTeos, Mirati, MSD, PharaMar, Promonotory Therapeutics, Roche and Seattle Genetics. B.A.F. has acted as a consultant and/or adviser for Calidi, Merck, Pfizer, PrimeVax and Turnstone; has received research funding from BMS, Akkoya Biosciences, Hamamatsu, Incyte, Merck and Shimadzu; and is a founder of, holds stocks in, and has intellectual propertiy licensed to UbiVac. F.B. has acted as a consultant and/or adviser for Abbvie, ACEA, Amgen, AstraZeneca, Bayer, BMS, Boehringer-Ingelheim, Eisai, Lilly, Genentech, Ignyta, Innate Pharma, Ipsen, Loxo, Medimmune, Merck, MSD, Novartis, Pierre Fabre, Pfizer, Roche, Sanofi-Aventis, Summit Therapeutics and Takeda; and has non-financial interests in AstraZeneca, BMS, Innate Pharma, Merck, Mirati, Pierre Fabre and Roche. The other authors declare no competing interests.
